Daily Dosing for Bedaquiline in Patients with Tuberculosis-Reference-Cited by-同舟云学术

Daily Dosing for Bedaquiline in Patients with Tuberculosis

Published:2019-11 Issue:11 Volume:63 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Salinger David H.¹,Nedelman Jerry R.²,Mendel Carl²,Spigelman Melvin²,Hermann David J.³

Affiliation:

1. Certara, Inc., under contract with the Bill and Melinda Gates Foundation, Seattle, Washington, USA

2. TB Alliance, New York, New York, USA

3. Bill and Melinda Gates Foundation, Seattle, Washington, USA

Abstract

The bedaquiline regimen for the treatment of multidrug-resistant tuberculosis (MDR-TB) in adults is a loading dose of 400 mg QD for 2 weeks followed by 200 mg thrice weekly (TIW) for 22 weeks. Most TB antibiotics administered with bedaquiline are given QD.

Funder

Bill and Melinda Gates Foundation

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00463-19

Reference8 articles.

1. WHO. 2019. WHO tuberculosis fact sheet. https://www.who.int/en/news-room/fact-sheets/detail/tuberculosis. Accessed 22 January 2019.

2. U.S. Food and Drug Administration. 2012. Sirturo (bedaquiline) label. FDA Washington DC. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/204384s000lbl.pdf.

3. ClinicalTrials.gov. 2019. Safety and efficacy of various doses and treatment durations of linezolid plus bedaquiline and pretomanid in participants with pulmonary TB XDR-TB pre- XDR-TB or non-responsive/intolerant MDR-TB (ZeNix). https://clinicaltrials.gov/ct2/show/NCT03086486.

4. ClinicalTrials.gov. 2019. Trial to evaluate the efficacy safety and tolerability of BPaMZ in drug-sensitive (DS-TB) adult patients and drug-resistant (DR-TB) adult patients) (SimpliciTB). https://clinicaltrials.gov/ct2/show/NCT03338621.

5. Population Pharmacokinetics of Bedaquiline (TMC207), a Novel Antituberculosis Drug

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of therapeutic drug monitoring in the treatment of multi-drug resistant tuberculosis;Journal of Clinical Tuberculosis and Other Mycobacterial Diseases;2024-08

2. Second-line antituberculosis drug exposure thresholds predictive of adverse events in multidrug-resistant tuberculosis treatment;International Journal of Infectious Diseases;2024-03

3. A minimal PBPK model to accelerate preclinical development of drugs against tuberculosis;Frontiers in Pharmacology;2024-01-04

4. Effect of Bedaquiline and Delamanid Pharmacokinetics on Sputum Culture Conversion and Adverse Events in Drug-Resistant Tuberculosis;Therapeutic Drug Monitoring;2024-01-01

5. Mitochondrial dysfunction induced by bedaquiline as an anti-Toxoplasma alternative;Veterinary Research;2023-12-19